Yahoo
Tokyo - Delayed Quote JPY

Nippon Shinyaku Co., Ltd. (4516.T)

3,422.00 -25.00 (-0.73%)
At close: 3:24:36 PM GMT+9
Chart Range Bar
Loading chart for 4516.T
  • Previous Close 3,447.00
  • Open 3,476.00
  • Bid 3,387.00 x --
  • Ask 3,411.00 x --
  • Day's Range 3,413.00 - 3,485.00
  • 52 Week Range 3,203.00 - 6,529.00
  • Volume 188,700
  • Avg. Volume 487,544
  • Market Cap (intraday) 230.646B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 7.17
  • EPS (TTM) 477.32
  • Earnings Date Nov 13, 2026
  • Forward Dividend & Yield 124.00 (3.60%)
  • Ex-Dividend Date Mar 30, 2027
  • 1y Target Est 3,406.25

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

www.nippon-shinyaku.co.jp

2,309

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 10/19/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4516.T
37.63%
Nikkei 225 (^N225)
29.02%

1-Year Return

4516.T
8.47%
Nikkei 225 (^N225)
36.50%

3-Year Return

4516.T
32.77%
Nikkei 225 (^N225)
106.64%

5-Year Return

4516.T
55.89%
Nikkei 225 (^N225)
122.31%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 49.07B
Earnings 10.11B
Profit Margin 20.60%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
10B
20B
30B
40B
10.0%
12.0%
14.0%
16.0%
18.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

2,800.00 Low
3,406.25 Average
3,422.00 Current
4,200.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 9/18/2026
  • Market Cap

    232.67B

  • Enterprise Value

    160.10B

  • Trailing P/E

    7.83

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.36

  • Price/Book (mrq)

    0.79

  • Enterprise Value/Revenue

    0.94

  • Enterprise Value/EBITDA

    3.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.51%

  • Return on Assets (ttm)

    6.93%

  • Return on Equity (ttm)

    11.54%

  • Revenue (ttm)

    180.29B

  • Net Income Avi to Common (ttm)

    31.56B

  • Diluted EPS (ttm)

    477.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    72.7B

  • Total Debt/Equity (mrq)

    0.87%

  • Levered Free Cash Flow (ttm)

    19.74B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: